MedTrace Logo

Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD

NCT05867914 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2024-02-14

No results posted yet for this study

Summary

A trial to evaluate the safety, tolerability, and functionality of 3P-100, in subjects with Pulmonary Hypertension (PH) accompanying Interstitial Lung Disease (ILD), PH-ILD

Conditions

  • Hypertension, Pulmonary
  • Lung Diseases, Interstitial

Interventions

DEVICE

Inhaled Nitric Oxide (iNO)

eNOfit system delivering iNO

Sponsors & Collaborators

  • Third Pole Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Philip Silkoff, MD · Chief Medical Officer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-04
Primary Completion
2024-02-10
Completion
2024-03-29
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05867914 on ClinicalTrials.gov